Outcome in patients with peripheral T-cell lymphoma treated with pralatrexate, single center experience

• Published in: Turkish journal of internal medicine (Online) Vol. 4; no. 1; pp. 20 - 24
• Main Authors: AKDENİZ, Aydan, YILMAZ, Nurcan, KOYUNCU, Mahmut Bakır, TOMBAK, Anıl
• Format: Journal Article
• Language: English
• Published: Nizameddin KOCA 29.01.2022
• Subjects: non-hodgkin lymphoma; peripheral t-cell lymphoma; pralatrexate
• ISSN: 2687-4245; 2687-4245
• DOI: 10.46310/tjim.984313

Background: Peripheral T-cell lymphoma (PTCL) accounts for 10-15% of all non-Hodgkin lymphomas. Five-year overall survival is very poor in all subtypes except in ALK positive anaplastic large cell lymphomas (ALCL). Patients in relapsed-refractory (RR) setting, treatment options are very limited, particularly in patients with poor performance or advanced age. Pralatrexate has been shown to improve remission and survival rates in RR PTCL. We aimed to evaluate the response rates, efficacy and adverse event profile of pralatrexate used in RR PTCL in our center. Material and Methods: Patients followed in hematology department of Mersin University with the diagnosis of RRPTCL and treated with pralatrexate were included in study. Their demographical and clinical data were documented. Response to treatment with pralatrexate was evaluated. Results: Median follow up time was 14 months and mean age at diagnosis was 50.6 (±17.9) in totally 11 patients. Patients received median 2 cycles of pralatrexate. Six patients were refractory to treatment while 5 patients achieved at least partial remission. Conclusions: PTCL has the worst prognosis among all types of lymphomas. Cure rates are still low and new therapeutic options are needed.